These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 34816454)

  • 21. Associations of motor neuron disease research productivity and socioeconomic factors in Southeast Asia: a bibliometric analysis.
    Turalde CWR; Espiritu AI; Jamora RDG
    Arq Neuropsiquiatr; 2021 Nov; 79(11):1002-1011. PubMed ID: 34816988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Calcium bombs" as harbingers of synaptic pathology and their mitigation by magnesium at murine neuromuscular junctions.
    Dissanayake KN; Redman RR; Mackenzie H; Eddleston M; Ribchester RR
    Front Mol Neurosci; 2022; 15():937974. PubMed ID: 35959105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis.
    Jayasinghe M; Jena R; Singhal M; Jain S; Karnakoti S; Silva MS; Kayani AMA
    Cureus; 2022 Jun; 14(6):e25960. PubMed ID: 35855239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.
    Tarantino N; Canfora I; Camerino GM; Pierno S
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.
    Sawada H
    Expert Opin Pharmacother; 2017 May; 18(7):735-738. PubMed ID: 28406335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.
    Brooks BR; Pioro EP; Katz J; Takahashi F; Takei K; Zhang J; Apple S
    Muscle Nerve; 2022 Feb; 65(2):180-186. PubMed ID: 34816454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between the ALSFRS-R score and urate levels during 12 months of edaravone treatment for amyotrophic lateral sclerosis: Post hoc analysis of ALSFRS-R scores in clinical studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):593-602. PubMed ID: 36053970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between urate levels and amyotrophic lateral sclerosis functional score with edaravone treatment: Post hoc analysis of studies MCI186-16, MCI186-17, and MCI186-19.
    Takahashi F; Kano O; Nagano Y; Yoneoka T; Nelson S; Ushirogawa Y
    Muscle Nerve; 2022 Nov; 66(5):583-592. PubMed ID: 36054038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    Takei K; Takahashi F; Liu S; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):49-54. PubMed ID: 28872913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis.
    Takahashi F; Takei K; Tsuda K; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):32-39. PubMed ID: 28872914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
    Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
    PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials.
    van Eijk RPA; de Jongh AD; Nikolakopoulos S; McDermott CJ; Eijkemans MJC; Roes KCB; van den Berg LH
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 May; 22(3-4):300-307. PubMed ID: 33527843
    [No Abstract]   [Full Text] [Related]  

  • 34. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of
    Shefner JM; Andrews JA; Genge A; Jackson C; Lechtzin N; Miller TM; Cockroft BM; Meng L; Wei J; Wolff AA; Malik FI; Bodkin C; Brooks BR; Caress J; Dionne A; Fee D; Goutman SA; Goyal NA; Hardiman O; Hayat G; Heiman-Patterson T; Heitzman D; Henderson RD; Johnston W; Karam C; Kiernan MC; Kolb SJ; Korngut L; Ladha S; Matte G; Mora JS; Needham M; Oskarsson B; Pattee GL; Pioro EP; Pulley M; Quan D; Rezania K; Schellenberg KL; Schultz D; Shoesmith C; Simmons Z; Statland J; Sultan S; Swenson A; Berg LHVD; Vu T; Vucic S; Weiss M; Whyte-Rayson A; Wymer J; Zinman L; Rudnicki SA
    Amyotroph Lateral Scler Frontotemporal Degener; 2021 May; 22(3-4):287-299. PubMed ID: 32969758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis.
    Stipancic KL; Yunusova Y; Berry JD; Green JR
    J Speech Lang Hear Res; 2018 Nov; 61(11):2757-2771. PubMed ID: 30383220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
    WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.